These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. De Corte BL J Med Chem; 2005 Mar; 48(6):1689-96. PubMed ID: 15771411 [No Abstract] [Full Text] [Related]
7. Support vector machines: development of QSAR models for predicting anti-HIV-1 activity of TIBO derivatives. Darnag R; Mostapha Mazouz EL; Schmitzer A; Villemin D; Jarid A; Cherqaoui D Eur J Med Chem; 2010 Apr; 45(4):1590-7. PubMed ID: 20110136 [TBL] [Abstract][Full Text] [Related]
8. Quantitative structure-activity relationships and comparative molecular field analysis of TIBO derivatised HIV-1 reverse transcriptase inhibitors. Hannongbua S; Pungpo P; Limtrakul J; Wolschann P J Comput Aided Mol Des; 1999 Nov; 13(6):563-77. PubMed ID: 10584215 [TBL] [Abstract][Full Text] [Related]
9. Data mining using template-based molecular docking on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone (TIBO) derivatives as HIV-1RT inhibitors. Sapre NS; Gupta S; Pancholi N; Sapre N J Mol Model; 2008 Nov; 14(11):1009-21. PubMed ID: 18642033 [TBL] [Abstract][Full Text] [Related]
10. CoMFA 3D-QSAR analysis of HIV-1 RT nonnucleoside inhibitors, TIBO derivatives based on docking conformation and alignment. Zhou Z; Madura JD J Chem Inf Comput Sci; 2004; 44(6):2167-78. PubMed ID: 15554687 [TBL] [Abstract][Full Text] [Related]
11. Conformation depends on 4D-QSAR analysis using EC-GA method: pharmacophore identification and bioactivity prediction of TIBOs as non-nucleoside reverse transcriptase inhibitors. Akyüz L; Sarıpınar E J Enzyme Inhib Med Chem; 2013 Aug; 28(4):776-91. PubMed ID: 22591319 [TBL] [Abstract][Full Text] [Related]
12. Quantitative structure-activity relationship studies of TIBO derivatives using support vector machines. Darnag R; Schmitzer A; Belmiloud Y; Villemin D; Jarid A; Chait A; Mazouz E; Cherqaoui D SAR QSAR Environ Res; 2010 Apr; 21(3-4):231-46. PubMed ID: 20544549 [TBL] [Abstract][Full Text] [Related]
13. Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms. Li D; Zhan P; De Clercq E; Liu X J Med Chem; 2012 Apr; 55(8):3595-613. PubMed ID: 22268494 [No Abstract] [Full Text] [Related]
14. Anti-HIV activity of HEPT, TIBO, and cyclic urea derivatives: structure-property studies, focused combinatorial library generation, and hits selection using substructural molecular fragments method. Solov'ev VP; Varnek A J Chem Inf Comput Sci; 2003; 43(5):1703-19. PubMed ID: 14502505 [TBL] [Abstract][Full Text] [Related]
16. A novel simple QSAR model for the prediction of anti-HIV activity using multiple linear regression analysis. Afantitis A; Melagraki G; Sarimveis H; Koutentis PA; Markopoulos J; Igglessi-Markopoulou O Mol Divers; 2006 Aug; 10(3):405-14. PubMed ID: 16896545 [TBL] [Abstract][Full Text] [Related]
17. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives. Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659 [TBL] [Abstract][Full Text] [Related]
18. "In silico" design of potential anti-HIV actives using fragment descriptors. Varnek A; Solov'ev VP Comb Chem High Throughput Screen; 2005 Aug; 8(5):403-16. PubMed ID: 16101580 [TBL] [Abstract][Full Text] [Related]
19. A group center overlap based approach for "3D QSAR" studies on TIBO derivatives. Sapre NS; Gupta S; Pancholi N; Sapre N J Comput Chem; 2009 Apr; 30(6):922-33. PubMed ID: 18785154 [TBL] [Abstract][Full Text] [Related]
20. Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs). Barreca ML; Carotti A; Carrieri A; Chimirri A; Monforte AM; Calace MP; Rao A Bioorg Med Chem; 1999 Nov; 7(11):2283-92. PubMed ID: 10632038 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]